‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
University of Sheffield5h
Survival rates for patients with operable bladder cancer significantly improved by immunotherapy before and after surgery
A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...
Healio1d
Recurrence, mortality rates better in nevus-associated vs. de novo acral melanoma
Recurrence-free survival and overall survival were more common in patients with nevus-associated acral melanoma compared with ...
BMJ4d
Dementia, survival rates, and nursing home admissions
Predicting need for nursing home care remains complex For clinicians it is an important and demanding task to inform patients with dementia and their relatives about the prognosis. As with malignant ...